Immunogenicity profile of rurioctocog alfa pegol in previously treated patients with severe congenital hemophilia A
Open Access
- 30 May 2024
- journal article
- research article
- Published by American Society of Hematology in Blood Advances
- Vol. 8 (11) , 2726-2739
Abstract
Rurioctocog alfa pegol is an extended–half-life full-length recombinant factor VIII (FVIII) bound to 20-kDa polyethylene glycol (PEG) that has been shown to be well tolerated and efficacious in the treatment and prevention of bleeding events in previously treated patients with severe hemophilia A. Here, we present a comprehensive analysis of immunogenicity data collected during 6 clinical studies of rurioctocog alfa pegol, including a total of 360 unique previously treated patients with severe hemophilia A. The analysis included treatment-emerging FVIII-neutralizing antibodies (FVIII inhibitors); preexisting and treatment-emerging antibodies binding to FVIII, PEG-FVIII, or PEG; and treatment-emerging antibodies binding to Chinese hamster ovary host cell proteins. Moreover, the potential association between the presence of these binding antibodies and adverse events (AEs) observed in patients was investigated, and the potential impact of these antibodies on the incremental recovery of rurioctocog alfa pegol in patients was analyzed. Overall, the data indicate that rurioctocog alfa pegol is not associated with any unexpected immunogenicity characteristics. Of 360 patients, 1 patient developed a transient FVIII inhibitor with a titer of 0.6 Bethesda units per mL, which was not associated with any serious AEs. Antibodies binding to FVIII, PEG-FVIII, or PEG were not detected at the time when the inhibitor was present. Moreover, 54 of 360 patients either entered the clinical studies with preexisting binding antibodies or developed these antibodies after exposure to rurioctocog alfa pegol. These antibodies were transient in most patients and did not show any causal relationship to either AEs or spontaneous bleeding episodes.Keywords
This publication has 40 references indexed in Scilit:
- Increased prevalence of inhibitors in Hispanic patients with severe haemophilia A enrolled in the Universal Data Collection databaseHaemophilia, 2012
- Prevalence and epitope specificity of non-neutralising antibodies in a large cohort of haemophilia A patients without inhibitorsThrombosis and Haemostasis, 2011
- Impact of polymorphisms of the major histocompatibility complex class II, interleukin‐10, tumor necrosis factor‐α and cytotoxic T‐lymphocyte antigen‐4 genes on inhibitor development in severe hemophilia AJournal of Thrombosis and Haemostasis, 2009
- Quantitation of anti–factor VIII antibodies in human plasmaBlood, 2009
- Homeostatic roles of naturally occurring antibodies: An overviewJournal of Autoimmunity, 2007
- Factor VIII half-life and clinical phenotype of severe hemophilia A.2005
- Environmental and genetic factors influencing inhibitor developmentSeminars in Hematology, 2004
- The Half-life of Infused Factor VIII Is Shorter in Hemophiliac Patients with Blood Group 0 than in those with Blood Group AThrombosis and Haemostasis, 2000
- Inhibitors occur more frequently in African–American and Latino HaemophiliacsHaemophilia, 1998
- Inter‐individual variation in half‐life of infused recombinant factor VIII is related to pre‐infusion von Willebrand factor antigen levelsBritish Journal of Haematology, 1995